spacer
home > epc > winter 2003 > poly(ortho esters) - a bioerodible polymer system specifically designed for drug delivery
PUBLICATIONS
European Pharmaceutical Contractor

Poly(ortho esters) - A Bioerodible Polymer System Specifically Designed for Drug Delivery

Bioerodible polymers are an important class of biomaterials that are assuming an increasingly important role in drug delivery, orthopedic applications and tissue engineering. While bioerodible polymers based on natural products such as collagen or various polysaccharides have been used in a number of applications, for reasons of availability, purity, lack of antigenicity and ability to tailor polymer properties, a majority of past and current applications have concentrated on synthetic polymers. Of these, the most important are poly(lactic acid), poly(glycolic acid) poly(lactic-co-glycolic acid) co-polymers, poly(ortho esters), polyanhydrides and poly(phospho esters). These will not be discussed in this order here, but will be grouped according to the mechanism of hydrolysis.

Polymers that Undergo Bulk Erosion

Bulk erosion can be defined as a hydrolysis process that occurs at a more or less uniform rate throughout the bulk of the material.

Polymers based on Lactic and Glycolic Acids Poly(lactic acid), poly(glycolic acid) and poly(lactic-co-glycolic acid) co-polymers were developed as materials to be used in surgical applications, be it reconstructive surgery such as poly(lactic acid) or use as sutures such as poly(glycolic acid) and poly(lactic-co-glycolic acid) co-polymers. Due to the fact that these polymers degrade to the natural metabolites lactic and glycolic acid, and because they had FDA approval as suture materials, it was logical that early research in drug delivery selected these materials as matrices for bioerodible drug delivery. However, poly(glycolic acid) is not useful as a drug delivery system because it is highly crystalline, high melting and insoluble in toxicologically acceptable solvents, which makes fabrication of drug delivery devices very difficult and limits its use to bioerodible suture applications.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Jorge Heller PhD, Principal Scientist at AP Pharma

Dr Heller has been with AP Pharma since 1994 after a long career at the Stanford Research Institute (now SRI International) and a short stay at ALZA. Dr Heller has been developing bioerodible polymers since 1970 and is the creator of poly(ortho esters), the subject matter of this article. Dr Heller received a BSc degree in Chemistry from the University of California in Berkeley and a PhD in Organic Chemistry from the University of Washington.

spacer
Dr Jorge Heller
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement